Wednesday, 15 Aug 2018

You are here

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

They merged data from two large British RA registries (British Society for Rheumatology Biologics Register-RA [safety data] and the Biologics in RA Genetics and Genomics Syndicate [serological samples]) to assess the effect of biologic drug levels in rheumatoid arthritis (RA) patients on all infections (AI) and SI (infections requiring hospitalisation, IV antibiotics or lead to death.

Serum samples and drug levels were measured at 3, 6,  and 12 months after biologic initiation and the risk of first and total infections within the first year was analysed.

The RA population (n=703) of predominantly female patients on biologics  - 286 etanercept, 179 adalimumab, 120 certolizumab, 104 tocilizumab and 14 infliximab were studied. The majority of enrolled patients were on their first biologic (89%). The adjusted hazard ratio for AI within  the first year differed significantly between the two groups with the HL group having a 50 percent higher risk of all infections (HR: 1.51; 95% CI: 1.14, 2.01).

The most common types of AI in the HL group were lower (34%) and upper (16%) respiratory tract infections, urinary tract infections (15%), skin infections including shingles (8%).

Serious inffections, however, were not increased with high vs. low doses of biologic exposure. 

This study suggests that monitoring drug levels may be helpful in prediction of infectious complications in RA patients.

Biologic dose tapering in patients with high biologic levels who were able to achieve stable remission may lower infection risk.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

IL-1 Suppression May Improve Dilated Cardiomyopathy


Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.